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Supplemental Figure S1 Supplemental Figure S3 . Decrease in FADS1 and ELVOL6 index activities in NASH patients. (a) Evaluation of ELOVL5 activity using c22:5n-6 to c20:5n-3; (b) evaluation of FADS2 activity using c18:3n-6 to c18:2n-6 ratio. (c) evaluation of SCD1 using c18:1n-9 to c18:0 ratio (d) both ELOVL5 and ELOVL6 activities using c18:1n-7 to c16:1n-7; (e) global ELOVL5. ELOVL6 and SCD1 activities using c18:1n-7 to c16:0 ratio; (f) both ELOVL5 and FADS1 activities using c20:4n-6 to c18:3n-6 ratio. (g) Global ELOVL5. FADS1 and FADS2 activities using 20:4n-6 to c18:2n-6 ratio towards the n-6 pathway, and (h) global ELOVL5 and FADS1 activities using 20:5n-3 to c18:3n-3 ratio towards the n-3 pathway. (i) Hepatic n-6 to n-3 ratio and n-3 index of the different study groups. in order to evaluate enzyme activities. a ratio between product-to-precursor of each reaction has been used as described before. 
